6-对甲苯胺基萘磺酸 | 7724-15-4

• 物质功能分类: 有机原料 - 氨基化合物 - 磺酸类氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-对甲苯胺基萘磺酸
• 中文别名: 6-对甲苯氨基-2-萘磺酸钾盐；2-对甲苯氨基萘-6-磺酸钾盐
• 英文名称: 6-p-toluidinonaphthalene-2-sulfonic acid
• 英文别名: 2-(p-Toluidinyl)naphthalene-6-sulfonic acid；6-(p-Toluidino)-2-naphthalene sulfonic acid；2-(p-toluidinyl)naphtalene-6-sulfonic acid；6-(p-toluidino)-2-naphthalenesulfonic acid；6-p-toluidino-2-naphthalenesulfonic acid；2-(p-toluidinyl)naphthalene-6-sulfonate；2-Naphthalenesulfonic acid, 6-[(4-methylphenyl)amino]-；6-(4-methylanilino)naphthalene-2-sulfonic acid
• CAS: 7724-15-4
• 化学式: C₁₇H₁₅NO₃S
• 分子量: 313.377
• InChiKey: VTRBOZNMGVDGHY-UHFFFAOYSA-N

物化性质

• 密度：
  1.370±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.058
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R38
• WGK Germany：
  3
• 海关编码：
  2921499090

SDS

Name:	6-P-Toluidine-2-Naphthalenesulfonic Acid 99% (Titr.) Material Safety Data Sheet
Synonym:	6-(4-Methylphenyl)amino-2-Naphthalenesulfonic Aci
CAS:	7724-15-4

Section 1 - Chemical Product MSDS Name:6-P-Toluidine-2-Naphthalenesulfonic Acid 99% (Titr.) Material Safety Data Sheet
Synonym:6-(4-Methylphenyl)amino-2-Naphthalenesulfonic Aci

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
7724-15-4	2-Naphthalenesulfonic Acid,6-(4-Methyl	ca 100	231-769-2

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 7724-15-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige to gray
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 250 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C17H15NO3S
Molecular Weight: 313.38

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 7724-15-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Naphthalenesulfonic Acid,6-(4-Methylphenyl)amino- - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 7724-15-4: No information available.
Canada
CAS# 7724-15-4 is listed on Canada's DSL List.
CAS# 7724-15-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 7724-15-4 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-对甲苯胺基萘磺酸 在 三氯氧磷 作用下， 以 吡啶 为溶剂， 生成 6-(对甲苯氨基)-2-萘磺酰氯
  参考文献：
  名称：

  分子内供体-受体系统

  摘要：

  摘要 简要回顾了 N-苯基氨基萘-邻苯二甲酸盐 (ANS) 系统的双荧光（S 1,np 和 S 1,ct 态发射）。6-N-甲基-N-苯基氨基-2-萘磺酸-N, N-二甲基酰胺也表现出双重荧光，如发射能量和Φ F 对溶剂极性参数ET (30) 的图所示。S 1,ct 发射的出现标志着发生分子内电子转移（即）过程的溶剂极性明显低于相应磺酸盐的极性。二甲基酰胺的荧光表现出对取代基变化的高度敏感性，表观哈米特 ϱ 值为约。-13 表示未取代的二甲基酰胺，-33 表示 N-甲基取代的二甲基酰胺。然后 ，

  DOI：

  10.1016/0022-2860(82)85259-9
• 作为产物：
  描述：

  乙烷,三氯氟- 、 6(or7)-氨基-2-萘磺酸 在 4-甲基苯胺盐酸盐 作用下， 生成 6-对甲苯胺基萘磺酸
  参考文献：
  名称：

  DE71158

  摘要：

  公开号：

文献信息

• [EN] TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS<br/>[FR] ADMINISTRATION CIBLÉE D'UN MÉDICAMENT FAISANT APPEL À DES COUPLEURS FONDÉS SUR L'AFFINITÉ
  申请人：INVICTUS ONCOLOGY PVT LTD

  公开号：WO2015148126A1

  公开（公告）日：2015-10-01

  The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

  当前的发明揭示了包括通过具有与靶向基团亲和力的分子连接到药物的靶向药物传递共轭物。通常，该共轭物包括一个靶向配体和一个感兴趣的分子，例如，一个治疗剂。靶向配体和感兴趣的分子通过一个亲和配体相互连接。该亲和配体进一步以共价或非共价方式连接到药物或治疗剂。药物可以被修改以使其更溶解，并使其在靶点处从连接分子中解离。
• COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES
  申请人：Lin Paulo J.C.

  公开号：US20120264810A1

  公开（公告）日：2012-10-18

  Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that binds a Na+/K+ ATPase to enhance uptake of the lipid particle b\ the cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound that enhances uptake of the lipid particles b\ the cell The methods and compositions are useful in delivering a therapeutic agent to a cell, e g for the treatment of a disease or disorder in a subject

  描述了用于增强细胞对脂质粒的摄取的组成物、方法和化合物。在特定的实施例中，发明的方法包括将细胞与脂质粒和一种与Na+/K+ ATPase结合的化合物接触，以增强细胞对脂质粒的摄取。在实践方法中使用的相关组成物包括包含一种共轭化合物的脂质粒，该共轭化合物增强细胞对脂质粒的摄取。这些方法和组成物可用于将治疗剂递送到细胞中，例如用于治疗主体中的疾病或失调。
• [EN] LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS<br/>[FR] LIPIDES DESTINÉS À ÊTRE UTILISÉS DANS DES FORMULATIONS NANOPARTICULAIRES LIPIDIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2019036028A1

  公开（公告）日：2019-02-21

  Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein G1, G1', G2, G2', G3, L1, L1', L2, L2', X, X', Y and Y' are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

  提供具有以下结构（I）或其药物可接受的盐、互变异构体或立体异构体的化合物，其中G1、G1'、G2、G2'、G3、L1、L1'、L2、L2'、X、X'、Y和Y'按本文中定义。还提供了这些化合物作为脂质纳米粒子制剂组成部分用于递送治疗剂的应用，包含这些化合物的组合物及其使用和制备方法。
• Lipid probes and uses thereof
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10168342B2

  公开（公告）日：2019-01-01

  Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

  披露了用于识别脂质结合蛋白作为药物结合靶点的方法、组合物、探针、检测和试剂盒。此外，还披露了用于绘制脂质结合蛋白上的配体结合位点、识别脂质结合蛋白、生成药物-脂质结合蛋白轮廓、高通量药物筛选以及识别作为潜在脂质结合蛋白配体的药物的方法、组合物和探针。
• LIPIDOSOME PREPARATION, PREPARATION METHOD AND APPLICATION THEREOF
  申请人：BIOMICS BIOTECHNOLOGIES CO., LTD.

  公开号：US20150272886A1

  公开（公告）日：2015-10-01

  The present invention discloses a liposome formulation, its preparation method, and its application in the treatment of diseases caused by abnormal gene expression. The liposome formulation comprises complementary cationic lipid pairs, phospholipids, and long-circulating lipids. The method of preparing the liposome formulation comprises: mixing the complementary cationic lipid pairs with the phospholipid and the long-circulating lipid to generate pre-formed vesicles; and then mixing the pre-formed vesicles with the nucleic acid solution to generate the liposome-nucleic acid formulation. This liposome formulation provided by the present invention is easily prepared; and in the treatment of diseases caused by abnormal gene expression, the liposome formulation can be used to deliver in vivo therapeutic agents, including nucleic acids.

  本发明公开了一种脂质体配方，其制备方法以及在治疗由异常基因表达引起的疾病中的应用。该脂质体配方包括互补的阳离子脂质对、磷脂和长循环脂质。制备该脂质体配方的方法包括：将互补的阳离子脂质对与磷脂和长循环脂质混合以生成预形成的囊泡；然后将预形成的囊泡与核酸溶液混合以生成脂质体-核酸配方。本发明提供的这种脂质体配方易于制备；在治疗由异常基因表达引起的疾病中，可以使用该脂质体配方来输送体内治疗剂，包括核酸。